Stocks · News reference

Bausch + Lomb shares are trading lower. The company announced the appointment of Chairman Thomas Appio as interim CEO following Brent Saunders' departure, while also indicating it expects to raise full-year 2026 adjusted EBITDA guidance.

Oct 12, 2026, 2:06 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGAROct 13, 2026, 10:09 AMSEC EDGAR
8-K filing — Bausch & Lomb Corp (BLCO)
Filed: 2026-10-13 AccNo: 0000950103-26-015460 Size: 372 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BLCO
BenzingaOct 12, 2026, 6:13 PMNeeraj Jain
Why Is Bausch + Lomb Stock Falling Monday?
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
BHC BLCO
BenzingaOct 12, 2026, 10:48 AMBenzinga Newsdesk
Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D
Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The
BHC BLCO